Protocatechuic Acid Crystals for Enveloped Virus Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating enveloped viruses, such as coronaviruses and influenza, rely heavily on chemical approaches and lack effective physical disruption strategies, which are necessary for targeting the vulnerable viral envelope to prevent infection.
Innovation Solution
Administering protocatechuic acid crystals, which have sharp protrusions and a low pH, to physically disrupt the viral envelope and inhibit viral entry into host cells, thereby targeting and inactivating enveloped viruses through physical and biochemical mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical methods are used to treat enveloped viruses, then antiviral activity is achieved, but physical disruption of the viral envelope is insufficient
Solution Approach 1:
The patent replaces purely chemical antiviral mechanisms with a physical disruption mechanism using crystal structures. The crystals mechanically disrupt the viral envelope through their physical structure, complementing or replacing chemical antiviral actions, thereby addressing the insufficiency of chemical methods alone.
Solution Approach 2:
The invention combines crystal structures with antiviral compositions to create a composite therapeutic approach. This combination allows simultaneous physical disruption of the viral envelope and biochemical inhibition of viral replication, achieving superior antiviral effectiveness compared to chemical methods alone.
2Object-affected harmful factors
If physical disruption methods are used to target viral envelopes, then viral entry is inhibited, but lack of sustained antiviral protection
Solution Approach 1:
The patent employs crystals that provide continuous physical disruption activity throughout the viral replication cycle. The crystalline structure maintains its disruptive capability over time, ensuring sustained antiviral protection rather than transient effect, thereby addressing the duration limitation of physical disruption methods.
Solution Approach 2:
The invention utilizes the stable physical parameters of crystal structures (shape, size, surface area) to provide consistent antiviral activity. The crystals maintain their structural integrity and disruptive capability over extended periods, achieving prolonged protection against viral entry and replication.
3Object-affected harmful factors
If crystals with sharp edges are used to disrupt viral spikes, then physical disruption is achieved, but potential tissue damage to host cells
Solution Approach 1:
The patent employs crystals with specifically engineered local properties - sharp edges concentrated at the crystal surface for viral envelope disruption, while the overall crystal structure and delivery system are designed to minimize harm to host tissues. The local sharpness is sufficient for viral disruption without causing widespread tissue damage.
Solution Approach 2:
The invention uses biodegradable or easily excreted crystal compounds that perform their disruptive function and then disappear from the body. This disposable approach ensures that the sharp crystal structures provide necessary viral disruption without causing long-term tissue damage, as the crystals are metabolized or excreted quickly after serving their purpose.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of protocatechuic acid crystals effectively disrupts the viral envelope, inactivates enveloped viruses, and provides prolonged antiviral protection by being absorbed into the body, where it remains active for several days, offering a multi-step inactivation process that limits viral replication and entry.
Implementation Method 1
The initial disruption is physical based upon the sharp protrusions of the PCA crystal
Implementation Method 2
PCA has a low pH that further destroys the exposed RNA and or DNA
Data Source
AI summary
In embodiments, a method of treating a disease or condition caused by an enveloped virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals and disrupting the viral envelope of the enveloped virus. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. The enveloped virus may be a coronavirus. The enveloped virus may be a virus of the family Orthomyxoviridae.